Skip to main content
. 2021 Apr 6;124(12):1988–1996. doi: 10.1038/s41416-021-01363-4

Table 1.

The positive proportion of factors examined in post-surgical samples.

Training cohort HCC (n = 804) LC (n = 166) FNH (n = 57) LA (n = 15) DN (n = 3) ICC (n = 145) Solid tumours (n = 129)
AFP RNAscope 60.4% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
AFP IHC 35.7% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
AFP ELISA 39.2% 1.8% 1.8% 0.0% 0.0% 0.0% 0.0%
GPC3 IHC 80.0% 15.7% 0.0% 0.0% 33.3% 0.7% 0.8%
HepPar-1 IHC 84.1% 83.1% 96.5% 93.3% 100.0% 2.1% 0.0%
Arg-1 IHC 61.2% 56.6% 61.4% 53.3% 100.0% 0.7% 0.0%
Validation cohort HCC (n = 477) LC (n = 25) FNH (n = 11) LA (n = 6) DN (n = 5) ICC (n = 84) Solid tumours (n = 34)
AFP RNAscope 66.5% 4.0% 0.0% 0.0% 0.0% 0.0% 0.0%
AFP IHC 33.8% 4.0% 0.0% 0.0% 0.0% 0.0% 0.0%
AFP ELISA 37.7% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
GPC3 IHC 65.6% 24.0% 0.0% 0.0% 60.0% 2.4% 0.0%
HepPar-1 IHC 72.7% 84.0% 81.8% 66.7% 80.0% 2.4% 0.0%
Arg-1 IHC 69.4% 80.0% 72.7% 83.3% 100.0% 0.0% 0.0%
Test cohort HCC (n = 100) LC (n = 8) FNH (n = 18) LA (n = 16) DN (n = 20) ICC (n = 32) Metastatic carcinoma (n = 61)
AFP RNAscope 45.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
AFP IHC 28.0% 12.5% 0.0% 0.0% 5% 0.0% 0.0%
AFP ELISA 62.0% 12.5% 0.0% 0.0% 0.0% 0.0% 1.6%
GPC3 IHC 66.0% 0.0% 0.0% 0.0% 20% 3.1% 18.0%
HepPar-1 IHC 81.0% 100% 100% 100% 100% 6.3% 1.6%
Arg-1 IHC 61.0% 100% 100% 100% 100% 0.0% 0.0%

HCC hepatocellular carcinoma, LC liver cirrhosis, FNH focal nodular hyperplasia, LA liver adenoma, DN dysplastic nodule, ICC intrahepatic cholangiocarcinoma, Solid tumours 15 types of non-HCC cancers (described in Fig. 1), Metastatic carcinoma 14 types of non-HCC cancers (described in Fig. 1), AFP ELISA AFP serum level >400 ng/ml was identified positive.